Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi
Related Experiment Video
Updated: Sep 25, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
Stephen B Gordon1, Stonard Kanyanda, Amanda L Walsh
1Wellcome Trust Research Laboratories, University of Malawi, Liverpool, UK. sgordon@mlw.medcol.mw
Insights
New conjugate vaccines help prevent Streptococcus pneumoniae infections but have limited serogroup coverage. Serogrouping data from Malawi shows a 9-valent vaccine could cover 66% of invasive pediatric isolates.
Area of Science:
- Medical Microbiology
- Vaccinology
- Epidemiology
Background:
- Streptococcus pneumoniae causes significant childhood and adult morbidity and mortality globally.
- Pneumococcal conjugate vaccines (PCVs) are effective but limited by serogroup coverage.
- Malawi faces a substantial burden of invasive pneumococcal disease.
Purpose of the Study:
- To determine the serogroup distribution of invasive and carried Streptococcus pneumoniae isolates in Malawi.
- To evaluate the potential impact of existing and next-generation pneumococcal conjugate vaccines in this population.
Main Methods:
- Collection of nasopharyngeal swabs and blood cultures from children and adults in Malawi.
- Serotyping of Streptococcus pneumoniae isolates using culture-based methods.
- Analysis of serotype coverage provided by 7-valent and 9-valent pneumococcal conjugate vaccines.
Main Results:
- The 7-valent PCV would cover 41% of invasive pediatric isolates and 25% of adult invasive isolates.
- A 9-valent PCV, including serotypes 1 and 5, demonstrated improved coverage.
- The 9-valent PCV would cover 66% of invasive pediatric isolates and 55% of adult invasive isolates.
Conclusions:
- Current pneumococcal conjugate vaccines offer suboptimal protection in Malawi.
- Expanding vaccine valency, particularly to include serotypes 1 and 5, significantly enhances coverage for invasive pneumococcal disease in Malawian children and adults.
- These findings support the need for vaccine strategies tailored to local serotype prevalence.
Abstract:
Streptococcus pneumoniae infections can be prevented by using new conjugate vaccines, but these vaccines have limited serogroup coverage. We report the first serogrouping data from carried and invasive isolates obtained from children and adults in Malawi. The 7-valent vaccine would cover 41% of invasive isolates from children and 25% from adults. A 9-valent vaccine, including types 1 and 5, would cover 66% of invasive isolates from children and 55% from adults.
Related Concept Videos
Vaccinations
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Vaccines
Smallpox
Preventive Healthcare Services
Primary Healthcare Services
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...

